Summary:
A Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17 Years) with Attention Deficit Hyperactivity Disorder
Qualified Participants Must:
• Be between 12 and 17 years of age
•
Be diagnosed with ADHD
Qualified Participants May Receive:
Physician evaluation;
Study medication;
Compensation